Environmentally classified pharmaceuticals

Two substances may have the same risk values but different PBT values, but the risk assessment can also be different even if the PBT values are the same. When assessing a medication's environmental impact, consideration should be given to both environmental risk and environmental hazard since bioaccumulation and persistence are not included in the risk assessment.

The Swedish Association of the Pharmaceutical Industry conducted the environmental risk assessment, beginning in 2005.

How to read the table

Last updated: 2011-08-19

« New search


L Antineoplastic and immunomodulating agents

 Substance  Risk  PBT  P  B  T  Volume in DDD
Antineoplastic agents
alemtuzumab exempt        
bevacizumab exempt        
cetuximab exempt        
ofatumumab exempt        
rituximab exempt        
trastuzumab exempt        
pemetrexed insigni-
ficant
1 0 0 1
temozolomide insigni-
ficant
1 0 0 1
hydroxy-
carbamide
insigni-
ficant
3 3 0 0
gemcitabine insigni-
ficant
5 3 0 2
imatinib insigni-
ficant
5 3 0 2
cladribine insigni-
ficant
5
N.B.
3
N.B.
0 2
gefitinib insigni-
ficant
5
N.B.
3 0 2
N.B.
capecitabine insigni-
ficant
6 3 0 3
erlotinib insigni-
ficant
6
N.B.
3 0 3
N.B.
sunitnib insigni-
ficant
6
N.B.
3
N.B.
0 3
nilotinib insigni-
ficant
9 3 3 3
dasatinib insigni-
ficant
9
N.B.
3 0 3
N.B.
bortezomib insigni-
ficant
- - - 3
sorafenib low 9 3 3 3
topotecan cannot be excl 1
N.B.
0 0 1
N.B.
busulfan cannot be excl 2
N.B.
0 0 2
N.B.
chlorambucil cannot be excl 2
N.B.
0 0 2
N.B.
melphalan cannot be excl 2
N.B.
0 0 2
N.B.
etoposide cannot be excl 3
N.B.
3
N.B.
0 0
N.B.
carboplatin cannot be excl 4
N.B.
3
N.B.
0 1
N.B.
mercaptopurine cannot be excl 4
N.B.
3 0 1
N.B.
cyclophos-
phamide
cannot be excl 5 3 0 2
mitomycin cannot be excl 6 3 0 3
tioguanine cannot be excl 6 3 0 3
ifosfamide cannot be excl 6
N.B.
3 0 3
N.B.
methyl aminolevulinate cannot be excl 6
N.B.
3 0 3
N.B.
oxaliplatin cannot be excl 6
N.B.
3 0 3
N.B.
paclitaxel cannot be excl 6
N.B.
0 3 3
N.B.
docetaxel cannot be excl 9
N.B.
3 3
N.B.
3
N.B.
doxorubicin cannot be excl - - - 2
N.B.
amsacrine cannot be excl - - - -
anagrelide cannot be excl - - - -
bexarotene cannot be excl - - - -
bleomycin cannot be excl - - - -
cytarabine cannot be excl - - - -
dacarbazine cannot be excl - - - -
daunorubicin cannot be excl - - - -
epirubicin cannot be excl - - - -
estramustine cannot be excl - - - -
fludarabine cannot be excl - - - -
idarubicin cannot be excl - - - -
irinotecan cannot be excl - - - -
clofarabine cannot be excl - - - -
lomustine cannot be excl - - - -
miltefosine cannot be excl - - - -
trabectedin cannot be excl - - - -
vincristine cannot be excl - - - -
vinorelbine cannot be excl - - - -
cisplatin   6
N.B.
3
N.B.
0 3
L02 Endocrine therapy
leuprorelin exempt         629 271 
anastrozole insigni-
ficant
5
N.B.
3 0 2
N.B.
797 520 
bicalutamide insigni-
ficant
6
N.B.
3 0 3
N.B.
1 167 048 
tamoxifen insigni-
ficant
9 3 3 3 1 013 477 
estradiol moderate 9 3 3 3 6 109 337 
C 3 209 075 
buserelin exempt         28 190 
goserelin exempt         286 186 
triptorelin exempt         62 384 
letrozole insigni-
ficant
4 3 0 1 288 440 
flutamide cannot be excl - - 3 - 35 679 
medroxy-
progesterone
cannot be excl - - - - 1 778 387 
C 1 018 136 
megestrol   9 3 3 3 90 
L03 Immunostimulants
filgrastim exempt         23 668 
glatiramer exempt         65 044 
interferon exempt         566 605 
lenograstim exempt        
pegfilgrastim exempt         55 200 
tasonermin exempt        
L04 Immunosuppressive agents
azathioprine cannot be excl - - - - 690 687 
methotrexate cannot be excl - - - - 2 052 530 
abatacept exempt         32 382 
adalimumab exempt        
anakinra exempt         11 984 
basiliximab exempt        
certolizumab pegol exempt         3 457 
daclizumab exempt        
eculizumab exempt         281 
efalizumab exempt        
etanercept exempt         512 068 
golimumab exempt        
immunoglobulin exempt        
infliximab exempt         553 183 
muromonab exempt         30 
ciclosporine insigni-
ficant
4 0 3 1 133 208 
leflunomide insigni-
ficant
5 3 0 2 60 150 
everolimus insigni-
ficant
8 3 3 2 6 748 
mycophenolic acid moderate 6 3 0 3 144 043